SCHEMBL2685328

SCHEMBL2685328

N[C@@H](Cc1ccccc1)C(=O)Nc1nnc(-c2ccncc2)s1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 3/20 0.60
NOX1 Q9Y5S8 4/20 0.56
KDM4E B2RXH2 6/20 0.54
ALDH1A1 P00352 5/20 0.54
HPGD P15428 4/20 0.54
HSD17B10 Q99714 2/20 0.52
GAA P10253 1/20 0.52
RCE1 Q9Y256 1/20 0.52
POLB P06746 1/20 0.51
HTT P42858 1/20 0.51
AKT1 P31749 1/20 0.51
MAPK8 P45983 1/20 0.50
MAPK10 P53779 1/20 0.50
ROCK1 Q13464 1/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC2 Q92769 2/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685334 1.00 GPR142 (0.60) GPR142NOX1KDM4EALDH1A1HPGD
SCHEMBL2685986 0.84 GPR142 (0.67) GPR142NOX1KDM4EROCK1
SCHEMBL2425005 0.84 RAB9A (0.60) KDM4EALDH1A1HPGDHDAC1HDAC2
SCHEMBL2684254 0.83 GPR142 (0.67) GPR142NOX1KDM4EALDH1A1HPGD
SCHEMBL2684771 0.81 GPR142 (0.64) GPR142NOX1AKT1ROCK1
SCHEMBL2684768 0.81 GPR142 (0.64) GPR142NOX1AKT1ROCK1
SCHEMBL4949860 0.80 NPC1 (0.52) GPR142KDM4E
Hydrochloric Acid SCHEMBL1600794 0.80 ROCK1 (0.56) GPR142NOX1AKT1ROCK1
SCHEMBL10260826 0.80 ROCK2 (0.64) GPR142AKT1ROCK1HDAC1HDAC2
SCHEMBL2802584 0.80 ROCK2 (0.64) GPR142AKT1ROCK1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885NOX1 2943/4885KDM4E 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.